Skip to main content

Client News

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

4th October 2023

Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress

4th October 2023

Carbios unveils major innovation in polyester recycling with new textile preparation line, in the presence of Roland Lescure, French Minister of Industry

2nd October 2023

Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

2nd October 2023

Newron appoints Margarita Chavez as board advisor

2nd October 2023

Abivax files registration statement for proposed initial public offering in the United States

29th September 2023

Abivax announces the release of its 2023 half-year financial report

29th September 2023

Ilmac 2023 in Basel was a resounding success

29th September 2023

Affluent Medical: H1 2023 RESULTS – Major advances in clinical programs – Extension of cash horizon to February 2024

28th September 2023

AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

28th September 2023

Carbios announces half-year 2023 financial results and corporate update

28th September 2023

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

27th September 2023

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

27th September 2023

Destiny Pharma: Destiny Pharma: Notice of XF Pipeline Update Meeting

27th September 2023

Abivax presents first-half 2023 financial results

21st September 2023

Destiny Pharma: Interim results for the six months ended 30 June 2023

20th September 2023

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

20th September 2023

Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer

19th September 2023

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

18th September 2023

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

18th September 2023

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities

13th September 2023

Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis

13th September 2023

Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval

13th September 2023

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

13th September 2023

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

11th September 2023

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

8th September 2023

Abivax provides business and operational update

7th September 2023

AdhereTech Appoints Innes Meldrum as President and Chief Executive Officer

6th September 2023

Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine

6th September 2023

Element Materials unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division

5th September 2023

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

5th September 2023

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

5th September 2023

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

5th September 2023

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

30th August 2023

Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations

23rd August 2023